# Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

> **NCT04706286** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 26 (estimated)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)

## Interventions

- **DRUG:** CKD-501, D759, D150
- **DRUG:** CKD-393 0.5/100/1000 mg

## Key facts

- **NCT ID:** NCT04706286
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-18
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-04-05
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706286, "Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04706286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*